Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
- PMID: 28283701
- DOI: 10.1007/s00259-017-3667-7
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging
Comment in
-
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging.Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1777-1778. doi: 10.1007/s00259-017-3682-8. Epub 2017 Mar 22. Eur J Nucl Med Mol Imaging. 2017. PMID: 28331955 No abstract available.
Comment on
-
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 27704193
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources